Chemical modification of rapamycin: the discovery of SDZ RAD.
Novartis Pharma AG, Basel, Switzerland.
R
R
Sedrani
S
S
Cottens
J
J
Kallen
W
W
Schuler
D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D015195:Drug Design; D000068338:Everolimus; D006360:Heat-Shock Proteins / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D015394:Molecular Structure; D011090:Polyenes / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D020123:Sirolimus; D013329:Structure-Activity Relationship; D022021:Tacrolimus Binding Proteins
D002352:Carrier Proteins; D004268:DNA-Binding Proteins; D006360:Heat-Shock Proteins; D007166:Immunosuppressive Agents; D011090:Polyenes; D000068338:Everolimus; D022021:Tacrolimus Binding Proteins; D020123:Sirolimus